Associate Professor Gavin Marx

Associate Professor
Medicine, Sydney Adventist Hospital Clinical School

Telephone 02 94765844
Fax 02 94821341

Map

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Lin, H., Mahon, K., Spielman, C., Gurney, H., Mallesara, G., Stockler, M., Bastick, P., Briscoe, K., Marx, G., Swarbrick, A., et al (2017). Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer. British Journal of Cancer, 116(8), 1002-1011. [More Information]
  • von Moos, R., Body, J., Egerdie, B., Stopeck, A., Brown, J., Fallowfield, L., Patrick, D., Cleeland, C., Damyanov, D., Palazzo, F., Marx, G., et al (2016). Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases. Supportive Care in Cancer, 24(3), 1327-1337. [More Information]
  • Li, B., Barnes, T., Chan, D., Naidoo, J., Lee, A., Khasraw, M., Marx, G., Kris, M., Clarke, S., Drilon, A., Pavlakis, N., et al (2016). The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials. Lung Cancer, 102, 21-27. [More Information]
  • Mahon, K., Lin, H., Castillo, L., Lee, B., Lee-Ng, K., Chatfield, M., Chiam, K., Breit, S., Brown, D., Molloy, M., Marx, G., Pavlakis, N., Boyer, M., Stockler, M., Horvath, L., et al (2015). Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer. British Journal of Cancer, 112(8), 1340-1348. [More Information]
  • Lakhanpal, R., Yoong, J., Joshi, S., Yip, D., Mileshkin, L., Marx, G., Dunlop, T., Hovey, E., Della Fiorentina, S., Venkateswaran, L., Tattersall, M., et al (2015). Geriatric assessment of older patients with cancer in Australia-A multicentre audit. Journal of Geriatric Oncology, 6(3), 185-193. [More Information]
  • McLachlan, J., Chan, D., Crumbaker, M., Marx, G. (2015). Neutrophil-lymphocyte ratio prior to steroids as a prognostic marker in men with metastatic castration-resistant prostate cancer. Cancer Treatment Communications, 4, 81-85. [More Information]
  • Lin, H., Castillo, L., Mahon, K., Chiam, K., Lee, B., Nguyen, Q., Boyer, M., Stockler, M., Pavlakis, N., Marx, G., Gurney, H., Horvath, L., et al (2014). Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. British Journal of Cancer, 110(10), 2462-2471. [More Information]
  • Mahon, K., Qu, W., Devaney, J., Paul, C., Castillo, L., Wykes, R., Chatfield, M., Boyer, M., Stockler, M., Marx, G., Gurney, H., Horvath, L., et al (2014). Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer. British Journal of Cancer, 111(9), 1802-1809. [More Information]
  • Hovey, E., De Souza, P., Marx, G., Parente, P., Rapke, T., Hill, A., Bonaventura, A., Michele, A., Craft, P., Abdi, E., et al (2014). Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy. Supportive Care in Cancer, 22(5), 1233-1242. [More Information]
  • Smith, M., Saad, F., Oudard, S., Shore, N., Fizazi, K., Sieber, P., Tombal, B., Damiao, R., Marx, G., Miller, K., et al (2013). Denosumab and Bone Metastasis-Free Survival in Men With Nonmetastatic Castration-Resistant Prostrate Cancer: Exploratory Analysis by Baseline Prostate-Specific Antigen Doubling Time. Journal of Clinical Oncology, 31(30), 3800-3806. [More Information]
  • von Moos, R., Body, J., Egerdie, B., Stopeck, A., Brown, J., Damyanov, D., Fallowfield, L., Marx, G., Cleeland, C., Patrick, D., et al (2013). Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. Supportive Care in Cancer, 21(12), 3497-3507. [More Information]
  • Won, A., Gurney, H., Marx, G., de Souza, P., Patel, M. (2013). Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer. BJU International, 112(4), E250-E255. [More Information]
  • McLachlan, J., Marx, G., Bridgman, M. (2013). Severe symptomatic hypocalcaemia following a single dose of denosumab. Medical Journal of Australia, 199(4), 242-243. [More Information]
  • Kao, S., Harvie, R., Paturi, F., Taylor, R., Davey, R., Abraham, R., Clarke, S., Marx, G., Cullen, M., Kerestes, Z., Pavlakis, N. (2012). The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine. Lung Cancer, 75(2), 248-254. [More Information]
  • Tebbutt, N., Murphy, F., Zannino, D., Wilson, C., Parry, M., Abdi, E., Strickland, A., Lowenthal, R., Marx, G., Karapetis, C., Shannon, J., Simes, R., et al (2011). Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. Annals of Oncology, 22(8), 1834-1838. [More Information]
  • Kao, S., Hovey, E., Marx, G. (2011). Second-line therapy for castrate-resistant prostate cancer: A literature review. Asia-Pacific Journal of Clinical Oncology, 7, 212-223. [More Information]
  • Hoovey, E., Marx, G., Kneebone, A., Patel, M., Shapiro, J. (2009). An Australian clinical perspective: management of hormone refractory (androgen-independent) prostate cancer. Asia Pacific Journal of Oncology and Hematology, 1, 1.
  • Gananadha, S., Hazebroek, E., Leibman, S., Berry, H., Osgood, L., Shon, I., Pavlakis, N., Marx, G., Smith, G. (2008). The utility of FDG-PET in the preoperative staging of esophageal cancer. Diseases of the Esophagus, 21(5), 389-394. [More Information]
  • Steer, C., Chrystal, K., Cheong, K., Galani, E., Marx, G., Strickland, A., Yip, D., Lofts, F., Gallagher, C., Thomas, H., et al (2006). Gemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with suboptimally debulked, advanced epithelial ovarian cancer. A phase II trial of sequential doublets. The GO-First Study. Gynecologic Oncology, 103(2), 439-445. [More Information]
  • Marx, G., Taylor, J., Goldstein, D. (2005). Outpatient treatment with subcutaneous interleukin-2, interferon alpha and fluorouracil in patients with metastatic renal cancer: an Australian experience. Internal Medicine Journal, 35(1), 34-38. [More Information]
  • Marx, G., Steer, C., Harper, P. (2005). Reply to the letter Limitations of bedside estimates of renal function" by M. J. Dooley and S. G. Poole". Annals of Oncology, 16, 990.
  • Ring, A., Marx, G., Steer, C., Prendiville, J., Ellis, P. (2003). Poor uptake of influenza vaccinations in patients receiving cytotoxic chemotherapy. International Journal of Clinical Practice, 57(6), 542-543. [More Information]
  • Galani, E., Marx, G., Steer, C., Culora, G., Harper, P. (2003). Pseudomyxoma peritonei: the 'controversial' disease. International Journal of Gynecological Cancer, 13(4), 413-418. [More Information]

2017

  • Lin, H., Mahon, K., Spielman, C., Gurney, H., Mallesara, G., Stockler, M., Bastick, P., Briscoe, K., Marx, G., Swarbrick, A., et al (2017). Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer. British Journal of Cancer, 116(8), 1002-1011. [More Information]

2016

  • von Moos, R., Body, J., Egerdie, B., Stopeck, A., Brown, J., Fallowfield, L., Patrick, D., Cleeland, C., Damyanov, D., Palazzo, F., Marx, G., et al (2016). Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases. Supportive Care in Cancer, 24(3), 1327-1337. [More Information]
  • Li, B., Barnes, T., Chan, D., Naidoo, J., Lee, A., Khasraw, M., Marx, G., Kris, M., Clarke, S., Drilon, A., Pavlakis, N., et al (2016). The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials. Lung Cancer, 102, 21-27. [More Information]

2015

  • Mahon, K., Lin, H., Castillo, L., Lee, B., Lee-Ng, K., Chatfield, M., Chiam, K., Breit, S., Brown, D., Molloy, M., Marx, G., Pavlakis, N., Boyer, M., Stockler, M., Horvath, L., et al (2015). Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer. British Journal of Cancer, 112(8), 1340-1348. [More Information]
  • Lakhanpal, R., Yoong, J., Joshi, S., Yip, D., Mileshkin, L., Marx, G., Dunlop, T., Hovey, E., Della Fiorentina, S., Venkateswaran, L., Tattersall, M., et al (2015). Geriatric assessment of older patients with cancer in Australia-A multicentre audit. Journal of Geriatric Oncology, 6(3), 185-193. [More Information]
  • McLachlan, J., Chan, D., Crumbaker, M., Marx, G. (2015). Neutrophil-lymphocyte ratio prior to steroids as a prognostic marker in men with metastatic castration-resistant prostate cancer. Cancer Treatment Communications, 4, 81-85. [More Information]

2014

  • Lin, H., Castillo, L., Mahon, K., Chiam, K., Lee, B., Nguyen, Q., Boyer, M., Stockler, M., Pavlakis, N., Marx, G., Gurney, H., Horvath, L., et al (2014). Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. British Journal of Cancer, 110(10), 2462-2471. [More Information]
  • Mahon, K., Qu, W., Devaney, J., Paul, C., Castillo, L., Wykes, R., Chatfield, M., Boyer, M., Stockler, M., Marx, G., Gurney, H., Horvath, L., et al (2014). Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer. British Journal of Cancer, 111(9), 1802-1809. [More Information]
  • Hovey, E., De Souza, P., Marx, G., Parente, P., Rapke, T., Hill, A., Bonaventura, A., Michele, A., Craft, P., Abdi, E., et al (2014). Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy. Supportive Care in Cancer, 22(5), 1233-1242. [More Information]

2013

  • Smith, M., Saad, F., Oudard, S., Shore, N., Fizazi, K., Sieber, P., Tombal, B., Damiao, R., Marx, G., Miller, K., et al (2013). Denosumab and Bone Metastasis-Free Survival in Men With Nonmetastatic Castration-Resistant Prostrate Cancer: Exploratory Analysis by Baseline Prostate-Specific Antigen Doubling Time. Journal of Clinical Oncology, 31(30), 3800-3806. [More Information]
  • von Moos, R., Body, J., Egerdie, B., Stopeck, A., Brown, J., Damyanov, D., Fallowfield, L., Marx, G., Cleeland, C., Patrick, D., et al (2013). Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. Supportive Care in Cancer, 21(12), 3497-3507. [More Information]
  • Won, A., Gurney, H., Marx, G., de Souza, P., Patel, M. (2013). Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer. BJU International, 112(4), E250-E255. [More Information]
  • McLachlan, J., Marx, G., Bridgman, M. (2013). Severe symptomatic hypocalcaemia following a single dose of denosumab. Medical Journal of Australia, 199(4), 242-243. [More Information]

2012

  • Kao, S., Harvie, R., Paturi, F., Taylor, R., Davey, R., Abraham, R., Clarke, S., Marx, G., Cullen, M., Kerestes, Z., Pavlakis, N. (2012). The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine. Lung Cancer, 75(2), 248-254. [More Information]

2011

  • Tebbutt, N., Murphy, F., Zannino, D., Wilson, C., Parry, M., Abdi, E., Strickland, A., Lowenthal, R., Marx, G., Karapetis, C., Shannon, J., Simes, R., et al (2011). Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. Annals of Oncology, 22(8), 1834-1838. [More Information]
  • Kao, S., Hovey, E., Marx, G. (2011). Second-line therapy for castrate-resistant prostate cancer: A literature review. Asia-Pacific Journal of Clinical Oncology, 7, 212-223. [More Information]

2009

  • Hoovey, E., Marx, G., Kneebone, A., Patel, M., Shapiro, J. (2009). An Australian clinical perspective: management of hormone refractory (androgen-independent) prostate cancer. Asia Pacific Journal of Oncology and Hematology, 1, 1.

2008

  • Gananadha, S., Hazebroek, E., Leibman, S., Berry, H., Osgood, L., Shon, I., Pavlakis, N., Marx, G., Smith, G. (2008). The utility of FDG-PET in the preoperative staging of esophageal cancer. Diseases of the Esophagus, 21(5), 389-394. [More Information]

2006

  • Steer, C., Chrystal, K., Cheong, K., Galani, E., Marx, G., Strickland, A., Yip, D., Lofts, F., Gallagher, C., Thomas, H., et al (2006). Gemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with suboptimally debulked, advanced epithelial ovarian cancer. A phase II trial of sequential doublets. The GO-First Study. Gynecologic Oncology, 103(2), 439-445. [More Information]

2005

  • Marx, G., Taylor, J., Goldstein, D. (2005). Outpatient treatment with subcutaneous interleukin-2, interferon alpha and fluorouracil in patients with metastatic renal cancer: an Australian experience. Internal Medicine Journal, 35(1), 34-38. [More Information]
  • Marx, G., Steer, C., Harper, P. (2005). Reply to the letter Limitations of bedside estimates of renal function" by M. J. Dooley and S. G. Poole". Annals of Oncology, 16, 990.

2003

  • Ring, A., Marx, G., Steer, C., Prendiville, J., Ellis, P. (2003). Poor uptake of influenza vaccinations in patients receiving cytotoxic chemotherapy. International Journal of Clinical Practice, 57(6), 542-543. [More Information]
  • Galani, E., Marx, G., Steer, C., Culora, G., Harper, P. (2003). Pseudomyxoma peritonei: the 'controversial' disease. International Journal of Gynecological Cancer, 13(4), 413-418. [More Information]

To update your profile click here. For support on your academic profile contact .